MARKET NEWS

Aileron Therapeutics Announces First Patients Treated in Phase 1b Trial of ALRN-6924 in Patients With p53-Mutated Neoadjuvant Breast Cancer
Rafael Pharmaceuticals Announces Corporate Name Change to Cornerstone Pharmaceuticals
Headlands Research & Pfizer Partnership to Significantly Improve Diversity in Clinical Trials
Avalo Therapeutics Announces First Patient Dosed in the Phase 2 PEAK Trial of AVTX-002 for the Treatment of Non-Eosinophilic Asthma 
Lilly Receives MHRA Marketing Authorisation for Abemaciclib in Combination With Endocrine Therapy for Adjuvant Treatment of People With HR+, HER2- High-Risk Early Breast Cancer
4D pharma Presents Late-Breaking Abstract From Phase 1/2 Trial of MRx-4DP0004 for the Treatment of Asthma

  FEATURED EDITORIAL

  COMPANY PROFILE

Lyophilization Technology, Inc. (LTI) is a Contract Development & Manufacturing Organization (CDMO) focused on all aspects of lyophilization for preparation of health care products. Clients leverage on our abilities for bringing new products to the clinic and implementing improvements for current products. Capitalize on over 25 years of excellence and our unparalleled capabilities in product development, process engineering, clinical manufacturing, and technical support. Click here for more.

Video Spotlight: Alcami Environmental Monitoring & Cleanroom Services

  EXCLUSIVE ONLINE CONTENT

 

Biomea Fusion Announces IND Candidate Selection: BMF-500, a Potential Best-in-Class Oral Covalent Inhibitor of FLT3

Biomea Fusion Announces IND Candidate Selection: BMF-500, a Potential Best-in-Class Oral Covalent Inhibitor of FLT3

Biomea Fusion, Inc. recently announced the nomination of its second product candidate, BMF-500, a highly selective and potent covalent investigational third-generation….

Caladrius Biosciences Announces IDMC Recommendation to Advance CLBS201 Trial for the Treatment of Diabetic Kidney Disease

Caladrius Biosciences Announces IDMC Recommendation to Advance CLBS201 Trial for the Treatment of Diabetic Kidney Disease

Caladrius Biosciences, Inc. recently announced the Independent Data Monitoring Committee (IDMC) overseeing the Phase 1b, open-label, proof-of-concept study of CLBS201 for the treatment of diabetic kidney disease (DKD) has reviewed the initial safety….

Croda Announces the New Pharma Business

Croda Announces the New Pharma Business

Croda recently announced that its Health Care division will now become Croda Pharma, bringing its core speciality excipient portfolio together with the recent acquisition, Avanti Polar Lipids and its….

MannKind Corporation Announces Agreement to Acquire V-Go Insulin Delivery Device From Zealand Pharma

MannKind Corporation Announces Agreement to Acquire V-Go Insulin Delivery Device From Zealand Pharma

MannKind Corporation recently announced it has entered into an agreement with Zealand Pharma A/S to acquire V-Go for $10 million, with additional sales-based milestones plus the cost of certain….

  WHITEPAPERS & WEBINARS

WEBINAR - Understanding Patch Composition for Effective Transdermal Delivery

WEBINAR - Understanding Patch Composition for Effective Transdermal Delivery

As the advantages of transdermal drug delivery grow, the global market for transdermal patches also is growing. Join DuPont™ Liveo™ Healthcare Solutions and Gattefossé Pharmaceuticals for a complimentary one-hour webinar to explore the current….

On Demand Webinar – Emergent CDMO: High-Speed Manufacturing Solutions for Your Viral Vaccine or Therapeutic

On Demand Webinar – Emergent CDMO: High-Speed Manufacturing Solutions for Your Viral Vaccine or Therapeutic

Emergent and groniger partner to present the benefits and features of the INTEGRA® high-speed aseptic fill line with isolator technology for viral vaccines and therapeutics.

  WHITEPAPERS & WEBINARS

WHITE PAPER - Poloxamer: A Simple & Powerful Solution for Accelerating Dissolution

WHITE PAPER - Poloxamer: A Simple & Powerful Solution for Accelerating Dissolution

Absorption of molecules from the gastrointestinal tract is an essential consideration when developing orally delivered medications. Solubility, the concentration of drug in solution, is essential for this to occur and it is important to also consider the dissolution rate of …

WHITE PAPER: Selecting In-Vitro Dissolution Methodologies for Amorphous Solid Dispersions

WHITE PAPER: Selecting In-Vitro Dissolution Methodologies for Amorphous Solid Dispersions

Achieving good in vivo performance is a key attribute for ensuring safety and efficacy of oral solid dosage (OSD) forms intended for systemic delivery. Yet, new drug targets and mecha­nisms of action continue to drive drug candidates’ phys­ical properties toward …

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

June 1 – Capsules
June 8 – Injection Devices